Results 201 to 210 of about 95,392 (311)

Monitoring of haematopoietic stem cell mobilization by targeted DNA methylation analysis for the British Journal of Haematology

British Journal of Haematology, EarlyView.
Wouter H. G. Hubens, Anke Diehlmann, Patrick Wuchter, Wolfgang Wagner   +3 more
wiley   +1 more source

Real‐world treatment patterns and outcomes in accelerated and blast‐phase myeloproliferative neoplasms: Insights from a large multi‐centre cohort analysis in the United Kingdom

British Journal of Haematology, EarlyView.
Summary This UK‐based retrospective analysis describes real‐world treatment patterns and outcomes in 175 patients with accelerated (AP, n = 69) or blast‐phase (BP, n = 106) ‘Philadelphia‐negative’ myeloproliferative neoplasms (MPN‐AP/BP) diagnosed between 2013 and 2025. Median age at transformation was 71 years.
Alexandros Rampotas, Gabriel Naylor‐Layland, Clare Brown, Ahmad Alabdulkarim, Jennifer Ryan, Frances Wadelin, Samah Alimam, Phyo Wint Wint Tun, Jonathan Lambert, Jennifer O'Sullivan, Andrew J. Wilson, Laith Tafesh, Andrew McGregor, Simone Claudiani, Andrew Innes, Emily Booth, James Leveson, Steve Knapper, Mamta Garg, Mani Dubey, Theodora Vatopoulou, Charlotte Brierley, Wai Ka Natalie Leung, Graham Greenfield, Mary Frances McMullin, Alesia Khan, Kate Milne, Duncan Brian, Anna Godfrey, Claire N. Harrison, Bethan Psaila, Patrick Harrington, Amy Kirkwood, Tim C. P. Somervaille, Donal P. McLornan, on behalf of the UK Blood Cancer Research Network MPN Clinical Study Group   +35 more
wiley   +1 more source

Clinical features and prognostic factors of adult systemic chronic active EBV disease: A retrospective analysis in Japan

British Journal of Haematology, EarlyView.
ALT and ferritin were adverse prognostic markers enabling risk stratification in adult systemic chronic active Epstein–Barr virus disease (sCAEBV). In hydroa vacciniforme lymphoproliferative disorder (HV‐LPD), Epstein–Barr virus (EBV) infection of CD4+ cells was associated with progression to sCAEBV.
Aika Fuseya, Masahide Yamamoto, Miwako Nishio, Ryo Kitabayashi, Akihiro Hirakawa, Hiroshi Yasui, Yoshihiro Umezawa, Keisuke Tanaka, Hayato Tamai, Yu Uemura, Kumi Oshima, Fumiaki Sano, Takehiko Mori, Ryuji Koike, Shouichi Ohga, Ayako Arai   +15 more
wiley   +1 more source

Factors influencing the treatment duration and visual prognosis of cytomegalovirus retinitis after allogeneic hematopoietic stem cell transplantation. [PDF]

Int J Ophthalmol
Wu S, Ding YH, Zhang C, Hou J.
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Efficacy analysis of iptacopan in a patient with thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: a case report. [PDF]

Front Immunol
Zhao Z, Guo L, Ge J, Wu W, Yue Y, Qiu Y, Li F, Hua W, Gu W, Lin Y.   +9 more
europepmc   +1 more source

Daunorubicin‐45 Vs. Daunorubicin‐60 for Induction in Intermediate‐Age Patients of AML: Results From a Randomized Trial

Cancer Science, EarlyView.
Daunorubicin dose escalation from 45 to 60 mg/m2 provides no clinical benefit for AML patients aged 55–65. A dose of 45 mg/m2 should remain the preferred regimen for this population. ABSTRACT Daunorubicin dose optimization remains crucial for AML treatment.
Chunlin Zhou, Le Li, Yan Li, Kaiqi Liu, Yuntao Liu, Dong Lin, Benfa Gong, Guangji Zhang, Xiaoyuan Gong, Qiuyun Fang, Bingcheng Liu, Shaowei Qiu, Ying Wang, Hui Wei, Yingchang Mi, Jianxiang Wang   +15 more
wiley   +1 more source

Effect of pretransplant spleen volume on the prognosis of acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation. [PDF]

Front Immunol
Liu W, Liu B, Pang L, Zhou L, Wang F, Zhang X, Wang Y.   +6 more
europepmc   +1 more source

An Immune Dysfunction Signature Score Predicts Survival in MDS Patients: Insights From a Longitudinal, Multicenter Study

Cancer Science, EarlyView.
An immune dysfunction score (IDS) provides independent prognostic information in MDS and CMML, complements current risk models, mirrors disease changes, and reflects underlying immune impairment. IDS may also highlight therapeutic sensitivities, supporting its use as a practical biomarker for risk stratification and clinical follow‐up.
Yu‐Hung Wang, Carmelo Gurnari, Valeria Visconte, Arda Durmaz, Luca Guarnera, Wan‐Hsuan Lee, Chi‐Yuan Yao, Andres Jerez, Kristian Gurashi, Kiran Batta, Hsin‐An Hou, Wen‐Chien Chou, Mrinal S. Patnaik, Jaroslaw Maciejewski, Daniel H. Wiseman, Chien‐Chin Lin, Hwei‐Fang Tien   +16 more
wiley   +1 more source

Clinical and translational advances in regulatory T cell-based strategies in allogeneic hematopoietic stem cell transplantation: highlights from ASH 2025. [PDF]

Exp Hematol Oncol
Yazdanparast S, Abroun S, Rostami T, Mohammadi S.   +3 more
europepmc   +1 more source